A set of 64 crucial parameters has been identified by researchers from more than 1,000 by which to judge stem cell-derived cardiac myocytes, making it possible, for perhaps the first time, for scientists and pharmaceutical companies to quantitatively judge and compare the value of the countless commercially available lines of stem cells.